BXA0.F LAVIPHARM S.A. NA EO 1
- Market cap
- EUR 241M
- P/E
- 47.0x
- P/B
- 4.27x
- ROE
- 10.6%
- Dividend yield
- 1.40%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is BXA0.F undervalued?
Graham numberBXA0.F trades 198.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LAVIPHARM S.A. NA EO 1 fundamental analysis
No fundamental analysis for LAVIPHARM S.A. NA EO 1 yet.
LAVIPHARM S.A. NA EO 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company w…
Full company profileLAVIPHARM S.A. NA EO 1 financial statements
LAVIPHARM S.A. NA EO 1 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 39.7M | 39.1M | 47.8M | 52.9M | 62.6M |
| Gross Profit | 15.9M | 17.6M | 22.2M | 25.1M | 30.3M |
| Operating Income | 5.38M | 3.74M | 4.59M | 5.47M | 9.01M |
| EBITDA | - | 5.60M | 9.60M | 10.2M | 14.6M |
| Net Income | 1.72M | 834K | 1.87M | 8.98M | 5.99M |
| EPS | 0.09 | 0.00 | 0.01 | 0.05 | 0.04 |
| Balance Sheet | |||||
| Total Assets | 52.7M | 114M | 115M | 125M | 130M |
| Total Liabilities | 62.7M | 73.9M | 72.0M | 72.5M | 73.8M |
| Shareholders' Equity | -9.98M | 40.3M | 42.7M | 53.0M | 56.4M |
| Cash & Short-term Investments | 1.64M | 18.2M | 8.44M | 5.59M | 6.11M |
| Cash Flow | |||||
| Operating Cash Flow | 4.11M | 3.35M | 284K | 4.64M | 6.67M |
| Capital Expenditure | 1.92M | 35.6M | 4.05M | 9.64M | 4.62M |
| Free Cash Flow | 2.19M | -32.3M | -3.77M | -5.00M | 2.05M |
| Ratios | |||||
| ROE | - | 2.1% | 4.4% | 17.0% | 10.6% |
| ROA | 3.3% | 0.7% | 1.6% | 7.2% | 4.6% |
| Net Profit Margin | 4.3% | 2.1% | 3.9% | 17.0% | 9.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LAVIPHARM S.A. NA EO 1 dividends
- Dividend yield
- 1.40%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 56.5%
- Ex-dividend date
- Jul 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 3.38M | 0.02 | 56.5% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2002 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns LAVIPHARM S.A. NA EO 1
- Insiders 61.09%
- Institutions 1.01%
- Public & others 37.90%
- Shares outstanding 171M
- Free float 64.0M
LAVIPHARM S.A. NA EO 1 company profile
- Company name
- LAVIPHARM S.A. NA EO 1
- Ticker
- BXA0.F
- ISIN
- GRS246003008
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 306
- Fiscal year end
- December
- Address
- 12, Agias Marinas Street, Paiania, Greece, 19002
- Phone
- 30 210 66 91 000
- Website
- lavipharm.com
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.
LAVIPHARM S.A. NA EO 1 management
10- Mr. Telemaque Jean LavidasCEO & Executive Board Member
- Mr. Vassilis BaloumisGroup CFO & Investor Relations Officer
- Mr. Anastasios SpyropoulosChief Manufacturing & Operations Officer
- Mr. Evangelos PaterakisChief Accountant
- Ms. Mariza AntonakiChief People & Technology Officer
- Mr. Nikos LadasChief Scientific Officer
- Ms. Eleana NikolopoulouGroup Head of Legal & Compliance and Corporate Secretary
- Mr. Ilias KonstantopoulosDirector of Marketing & Sales CHC
- Dr. Katerina TsardakaDirector of Business Development & Acquisitions
- Mr. Panagiotis GiannouleasDeputy CEO & Director